Elizabeth A. Morgan

Elizabeth A. Morgan

Auto-generated profile, based on publicly available information

Elizabeth A. Morgan

Department of Pathology, Brigham and Women's Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCMark W. Clemens
Mark W. Clemens
LML. Jeffrey Medeiros
L. Jeffrey Medeiros
CBCharles E. Butler
Charles E. Butler
KHKelly K. Hunt
Kelly K. Hunt
MFMichelle A. Fanale
Michelle A. Fanale
RMRoberto Nicolas Miranda
Roberto Nicolas Miranda
Purpose: Breast implant–associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach. Patients and Methods: In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported. A Prentice, Williams, and Peterson model was used to assess the rate of events for each therapeutic intervention. Results: The median and mean follow-up times were 45 and 30 months, respectively (range, 3 to 217 months). The median overall survival (OS) time after diagnosis of BI-ALCL was 13 years, and the OS rate was 93% and 89% at 3 and 5 years, respectively. Patients with lymphoma confined by the fibrous capsule surrounding the implant had better event-free survival (EFS) and OS than did patients with lymphoma that had spread beyond the capsule (P = .03). Patients who underwent a complete surgical excision that consisted of total capsulectomy with breast implant removal had better OS (P = .022) and EFS (P = .014) than did patients who received partial capsulectomy, systemic chemotherapy, or radiation therapy. Conclusion: Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL.

1 April 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SEShannon Elf
Shannon Elf
NANouran S. Abdelfattah
Nouran S. Abdelfattah
ECEdwin Chen
Edwin Chen
JPJavier Perales-Patón
Javier Perales-Patón
EREmily A. Rosen
Emily A. Rosen
AMAnn Mullally
Ann Mullally
Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear. Here, we demonstrate that expression of mutant CALR alone is sufficient to engender MPN in mice and recapitulates the disease phenotype of patients with CALR-mutant MPN. We further show that the thrombopoietin receptor MPL is required for mutant CALR-driven transformation through JAK–STAT pathway activation, thus rendering mutant CALR-transformed hematopoietic cells sensitive to JAK2 inhibition. Finally, we demonstrate that the oncogenicity of mutant CALR is dependent on the positive electrostatic charge of the C-terminus of the mutant protein, which is necessary for physical interaction between mutant CALR and MPL. Together, our findings elucidate a novel paradigm of cancer pathogenesis and reveal how CALR mutations induce MPN. Significance: The mechanism by which CALR mutations induce MPN remains unknown. In this report, we show that the positive charge of the CALR mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR and the thrombopoietin receptor MPL. Cancer Discov; 6(4); 368–81. ©2016 AACR. See related commentary by Stanley and Steidl, p. 344. This article is highlighted in the In This Issue feature, p. 331

14 July 2016 in Blood
Verified
Journal Article
Open access
PDF file
BLBenjamin L. Lampson
Benjamin L. Lampson
SKSiddha N. Kasar
Siddha N. Kasar
TMTiago R Matos
Tiago R Matos
EMElizabeth A. Morgan
Elizabeth A. Morgan
LRLaura Rassenti
Laura Rassenti
JBJennifer R. Brown
Jennifer R. Brown
Key Points: Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.

1 April 2016 in Cancer Cell
Verified
Journal Article
Closed access
ETElizabeth C. Townsend
Elizabeth C. Townsend
MMMark A. Murakami
Mark A. Murakami
ACAlexandra Christodoulou
Alexandra Christodoulou
ACAmanda L. Christie
Amanda L. Christie
JKJohannes Köster
Johannes Köster
DWDavid M. Weinstock
David M. Weinstock

25 August 2016 in Blood
Verified
Journal Article
Open access
PDF file
ALAbner Louissaint
Abner Louissaint
KSKristian T. Schafernak
Kristian T. Schafernak
JGJulia T. Geyer
Julia T. Geyer
AKAlexandra E. Kovach
Alexandra E. Kovach
MGMahmoud Ghandi
Mahmoud Ghandi
DWDavid M. Weinstock
David M. Weinstock
Key Points: PTNFL is a biologically distinct indolent lymphoma characterized by common MEK/ERK pathway mutations. The biology of PTNFL is not defined by age, as the mutational profile is similar in pediatric and adult cases.

18 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMichael J. Kluk
Michael J. Kluk
TATodd Ashworth
Todd Ashworth
HWHongfang Wang
Hongfang Wang
BKBirgit Knoechel
Birgit Knoechel
EMEmily F. Mason
Emily F. Mason
JAJon C. Aster
Jon C. Aster
Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been lacking. Here, we bridge this gap by developing an immunohistochemical (IHC) stain that detects a neoepitope created by the proteolytic cleavage event that activates NOTCH1. Following validation using xenografted cancers and normal tissues with known patterns of NOTCH1 activation, we applied this test to tumors linked to dysregulated Notch signaling by mutational studies. As expected, frequent NICD1 staining was observed in T lymphoblastic leukemia/lymphoma, a tumor in which activating NOTCH1 mutations are common. However, when IHC was used to gauge NOTCH1 activation in other human cancers, several unexpected findings emerged. Among B cell tumors, NICD1 staining was much more frequent in chronic lymphocytic leukemia than would be predicted based on the frequency of NOTCH1 mutations, while mantle cell lymphoma and diffuse large B cell lymphoma showed no evidence of NOTCH1 activation. NICD1 was also detected in 38% of peripheral T cell lymphomas. Of interest, NICD1 staining in chronic lymphocytic leukemia cells and in angioimmunoblastic lymphoma was consistently more pronounced in lymph nodes than in surrounding soft tissues, implicating factors in the nodal microenvironment in NOTCH1 activation in these diseases. Among carcinomas, diffuse strong NICD1 staining was observed in 3.8% of cases of triple negative breast cancer (3 of 78 tumors), but was absent from 151 non-small cell lung carcinomas and 147 ovarian carcinomas. Frequent staining of normal endothelium was also observed; in line with this observation, strong NICD1 staining was also seen in 77% of angiosarcomas. These findings complement insights from genomic sequencing studies and suggest that IHC staining is a valuable experimental tool that may be useful in selection of patients for clinical trials.